RETURNING CLINICAL DATA TO PATIENTS
Clinical trial volunteers are unsung heroes of medicine. The information they provide through clinical research is invaluable in advancing medical progress.
Pfizer believes that the data collected during a clinical trial should be returned to patient participants, if they wish, so that they may both better understand the research in which they took part and see and use the data gathered about their health.
Pfizer was the first biopharmaceutical company to return plain-language clinical trial data to participants, and we are working to expand our leadership in these important areas.
Principles for Responsible Data Sharing
Pfizer’s practices adhere to the principles for responsible data sharing laid out by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA).